Reversing neuromuscular blockade: Inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 6, 2016, Pages 819-833

  Haerter, Friederike ^a   Eikermann, Matthias ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

encapsulation; neuromuscular transmission block; Respiratory complications; reversal

Indexed keywords

CALABADION; CHOLINESTERASE INHIBITOR; CUCURBITURIL; CYSTEINE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; SUGAMMADEX; UNCLASSIFIED DRUG; CALABADION 1; EDROPHONIUM; FUSED HETEROCYCLIC RINGS; GAMMA CYCLODEXTRIN DERIVATIVE; SULFONIC ACID DERIVATIVE;

CLINICAL MEDICINE; DRUG EFFICACY; ENCAPSULATION; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MEDICAL HISTORY; NEUROMUSCULAR BLOCKING; REVIEW; SIDE EFFECT; ANESTHETIC RECOVERY; DELAYED EMERGENCE FROM ANESTHESIA; GENERAL ANESTHESIA;

ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; CHOLINESTERASE INHIBITORS; DELAYED EMERGENCE FROM ANESTHESIA; EDROPHONIUM; GAMMA-CYCLODEXTRINS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SULFONIC ACIDS;

EID: 84961217486     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1145667     Document Type: Review

References (134)

1. Rhoney DH, Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med. 2003; 18: 139-145.
2. Mascia MF, Koch M, Medicis JJ. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med. 2000; 28: 2300-2306.
3. Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115:743-751.
4. Murphy GS, Szokol JW, Avram MJ, et al. Residual neuromuscular block in the elderly: incidence and clinical implications. Anesthesiology. 2015; 123: 1322-1336.
5. Zhang B, Hepner DL, Tran MH, et al. Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009; 25: 943-950.
6. Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation. Anesthesiology. 2003; 98: 1049-1056.
7. Wilcox SR, Bittner EA, Elmer J, et al. Neuromuscular blocking agent administration for emergent tracheal intubation is associated with decreased prevalence of procedure-related complications. Crit Care Med. 2012; 40: 1808-1813.
8. Steingrub JS, Lagu T, Rothberg MB, et al. Treatment with neuromuscular blocking agents and the risk of in-hospital mortality among mechanically ventilated patients with severe sepsis. Crit Care Med. 2014; 42: 90-96.
9. Diaz-Gil D, Haerter F, Shane F, et al. A novel strategy to reverse general anesthesia by scavenging with the acyclic cucurbituril-type molecular container calabadion 2. Anesthesiology. under revision.
10. Wilson J, Collins AS, Rowan BO. Residual neuromuscular blockade in critical care. Crit Care Nurse. 2012; 32:e1-e10.
11. Eikermann M, Vogt FM, Herbstreit F, et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med. 2007; 175: 9-15.
12. Samet A, Capron F, Alla F, et al. Single acceleromyographic train-of-four, 100-Hertz tetanus or double-burst stimulation: which test performs better to detect residual paralysis? Anesthesiology. 2005; 102: 51-56.
13. McLean DJ, Diaz-Gil D, Farhan HN, et al. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015; 122: 1201-1213.
14. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth. 2007; 98: 302-316.
15. Kopman AF, Ng J, Zank LM, et al. Residual postoperative paralysis. Pancuronium versus mivacurium, does it matter? Anesthesiology. 1996; 85: 1253-1259.
16. Berg H, Viby-Mogensen J, Roed J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997; 41: 1095-1103.
17. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007; 62: 12-17.
18. Eikermann M, Zaremba S, Malhotra A, et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth. 2008; 101: 344-349.
19. Cammu G, de Baerdemaeker L, den Blauwen N, et al. Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol. 2002; 19: 129-134.
20. Butterly A, Bittner A, George E, et al. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth. 2010; 105: 304-309.
21. Fortier L-P, McKeen D, Turner K, et al. The RECITE study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg. 2015; 121: 366-372.
22. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010; 111: 120-128.
23. Sundman E, Witt H, Olsson R, et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000; 92: 977-984.
24. Herbstreit F, Peters J, Eikermann M. Impaired upper airway integrity by residual neuromuscular blockade: increased airway collapsibility and blunted genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2009; 110: 1253-1260.
25. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012; 345: e6329.
26. Staehr-Rye AK, Grabitz SD, Tharusan T, et al. Effects of residual paralysis on postoperative pulmonary function and hospital length of stay. 2015. ASA-Abstract A4026.
27. Pavllin EG, Holle RH, Schoene RB. Recovery of airway protection compared with ventilation in humans after paralysis with curare. Anesthesiology. 1989; 70: 381-385.
28. Dam WH, Guldmann N. Inadequate postanesthetic ventilation. Curare, anesthetic, narcotic, diffusion hypoxia. Anesthesiology. 1961; 22: 699-707.
29. Bodman RI. Evaluation of two synthetic curarizing agents in conscious volunteers. Br J Pharmacol Chemother. 1952; 7: 409-416.
30. Debaene B, Plaud B, Dilly M-P, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003; 98: 1042-1048.
31. Costa J, Evangelista T, Conceição I, et al. Repetitive nerve stimulation in myasthenia gravis-relative sensitivity of different muscles. Clin Neurophysiol. 2004;115:2776-2782.
32. Farhan H, Moreno-Duarte I, McLean D, et al. Residual paralysis: does it influence outcome after ambulatory surgery? Curr Anesthesiol Rep. 2014; 4: 290-302.
33. Eriksson LI. Reduced hypoxic chemosensitivity in partially paralysed man. A new property of muscle relaxants? Acta Anaesthesiol Scand. 1996; 40: 520-523.
34. Dahaba AA, Von Klobucar F, Rehak PH, et al. Comparison of a new piezoelectric train-of-four neuromuscular monitor, the ParaGraph, and the Relaxometer mechanomyograph. Br J Anaesth. 1999; 82: 780-782.
35. Trager G, Michaud G, Deschamps S, et al. Comparison of phonomyography, kinemyography and mechanomyography for neuromuscular monitoring. Can J Anaesth. 2006; 53: 130-135.
36. Eikermann M, Groeben H, Hüsing J, et al. Predictive value of mechanomyography and accelerometry for pulmonary function in partially paralyzed volunteers. Acta Anaesthesiol Scand. 2004; 48: 365-370.
37. Hemmerling TM, Le N. Brief review: neuromuscular monitoring: an update for the clinician. Can J Anaesth. 2007; 54: 58-72.
38. Frankel H, Jeng J, Tilly E, et al. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg. 1996; 62: 503-506.
39. Lien CA, Kopman AF. Current recommendations for monitoring depth of neuromuscular blockade. Curr Opin Anaesthesiol. 2014; 27: 616-622.
40. Todd MM, Hindman BJ, King BJ. The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. Anesth Analg. 2014; 119: 323-331.
41. Fuchs-Buder T, Fink H, Hofmockel R, et al. Application of neuromuscular monitoring in Germany. Anaesthesist. 2008; 57: 908-914.
42. Arbous MS, Meursing AEE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005; 102: 257-268.
43. Pal J. Physostigmin ein Gegengift des Curare. Zentralbl Physiol. 1900; 14: 255-258.
44. Patent: disubstituted carbamic acid esters of phenols containing a basic constituent. US 1905990 A. 1993.
45. Cowan SL. The action of eserine-like and curare-like substances on the responses of frogs nerve-muscle preparations to repetitive stimulation. J Physiol (Lond). 1938; 93: 215-262.
46. Highlights of prescribing information [Internet]. [cited 2015 Nov 22]. Available from: http://bloxiverz.com/data-info/uploads/2015/02/Bloxi-PI-2-15.pdf
47. Griffith H, Johnson E. The use of curare in general anesthesia. Anesthesiology. 1942; 3: 418-420.
48. Gray TC, Rees GJ. The role of apnoea in anaesthesia for major surgery. Br Med J. 1952; 2: 891-892.
49. Gray TC, Wilson F. The development and use of muscle relaxants in the United Kingdom. Anesthesiology. 1959; 20: 519-529.
50. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009; 103: 115-129.
51. Miller RD. Reversal of neuromuscular blockade. ASA Refresh Courses Anesthesiol. 1977;5:125-136.
52. Churchill-Davidson HC. The D-tubocurarine dilemma. Anesthesiology. 1965; 26: 132-133.
53. Baillard C, Clech C, Catineau J, et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005; 95: 622-626.
54. Osmer C, Vogele C, Zickmann B, et al. Comparative use of muscle relaxants and their reversal in three European countries: a survey in France, Germany and Great Britain. Eur J Anaesthesiol. 1996; 13: 389-399.
55. Naguib M, Kopman A, Lien CA, et al. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg. 2010; 111: 110-119.
56. Ledowski T, Ong JS, Flett T. Neuromuscular monitoring, muscle relaxant use, and reversal at a tertiary teaching hospital 2.5 years after introduction of sugammadex: changes in opinions and clinical practice. Anesthesiol Res Pract. 2015; 2015: 367937.
57. Cram DJ. Cavitands: organic hosts with enforced cavities. Science. 1983; 219: 1177-1183.
58. Warmuth R. The inner phase of molecular container compounds as a novel reaction environment. J Incl Phenom Macrocycl Chem. 2000; 37: 1-37.
59. Nair VP, Hunter JM. Anticholinesterases and anticholinergic drugs. Contin Educ Anaesth Crit Care Pain. 2004;4:164-168.
60. Colović MB, Krstić DZ, Lazarević-Pašti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013; 11: 315-335.
61. Barrow ME, Johnson JK. A study of the anticholenesterase and anticurare effects of some cholinesterase inhibitors. Br J Anaesth. 1966; 38: 420-431.
62. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4:131-138.
63. Gissen AJ, Katz RL, Karis JH, et al. Neuromuscular block in man during prolonged arterial infusion with succinylcholine. Anesthesiology. 1966; 27: 242-249.
64. Blondet B, Carpentier G, Ferry A, et al. Localization of butyrylcholinesterase at the neuromuscular junction of normal and acetylcholinesterase knockout mice. J Histochem Cytochem. 2010; 58: 1075-1082.
65. Miller RD, Eriksson LI, Fleisher L, et al. Millers anesthesia. 7th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.
66. Ramamurthy S, Shaker MH, Winnie AP. Glycopyrrolate as a substitute for atropine in neostigmine reversal of muscle relaxant drugs. Can J Anaesth. 1972; 19: 399-411.
67. Caldwell JE, Robertson EN, Baird WL. Antagonism of profound neuromuscular blockade induced by vecuronium or atracurium. Comparison of neostigmine with edrophonium. Br J Anaesth. 1986; 58: 1285-1289.
68. Haerter F, Simons JCP, Foerster U, et al. Comparative effectiveness of calabadion and sugammadex to reverse non-depolarizing neuromuscular-blocking agents. Anesthesiology. 2015;123:1337-1349.
69. Patent: cyclodextrins with anionic properties. US 3426011 A. 1969.
70. Summary of product characteristics-EMA [Internet]. [cited 2015 Nov 22]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000885/WC500052310.pdf
71. Schaller SJ, Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid. 2013; 8: 57-67.
72. Booij LHDJ. Cyclodextrins and the emergence of sugammadex. Anaesthesia. 2009; 64 (Suppl 1): 31-37.
73. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003; 99: 632-637.
74. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al. Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology. 2013;2:317-325.
75. Eikermann M, Houle T. Antagonism of neuromuscular block: all things are poison; only the dose makes a thing not a poison. Br J Anaesth. 2016;2:157-159.
76. Lien CA, Savard P, Belmont M, et al. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care. 2009; 24: 50-57.
77. Heerdt PM, Sunaga H, Savarese JJ. Novel neuromuscular blocking drugs and antagonists. Curr Opin Anaesthesiol. 2015; 28: 403-410.
78. Savarese JJ, McGilva JD, Sunaga H, et al. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology. 2010; 113: 58-73.
79. Savarese JJ, Belmont MR, Hashim MA, et al. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology. 2004; 100: 835-845.
80. Sunaga H, Malhotra JK, Yoon E, et al. Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology. 2010; 112: 900-909.
81. Belmont MR, Lien CA, Tjan J, et al. Clinical pharmacology of GW280430A in humans. Anesthesiology. 2004; 100: 768-773.
82. Janáky R, Varga V, Hermann A, et al. Mechanisms of L-cysteine neurotoxicity. Neurochem Res. 2000; 25: 1397-1405.
83. Slater RM, Pollard BJ, Doran BR. Prolonged neuromuscular blockade with vecuronium in renal failure. Anaesthesia. 1988; 43: 250-250.
84. Bevan DR, Archer D, Donati F, et al. Antagonism of pancuronium in renal failure: no recurarization. Br J Anaesth. 1982; 54: 63-68.
85. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology. 1986; 65: 6-12.
86. Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos. 2011; 32: 159-167.
87. Panhuizen IF, Gold SJA, Buerkle C, et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Br J Anaesth. 2015; 114: 777-784.
88. Staals LM, de Boer HD, van Egmond J, et al. Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats. J Anesth. 2011; 25: 241-246.
89. Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008; 101: 492-497.
90. Lenz A, Hill G, White PF. Emergency use of sugammadex after failure of standard reversal drugs. Anesth Analg. 2007; 104: 585-586.
91. Williams AR, Bailey M, Joye T, et al. Marked prolongation of the succinylcholine effect two hours after neostigmine reversal of neuromuscular blockade in a patient with chronic renal insufficiency. South Med J. 1999; 92: 77-79.
92. Bishop MJ, Hornbein TF. Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology. 1983; 58: 384-386.
93. Cronnelly R, Stanski DR, Miller RD, et al. Renal function and the pharmacokinetics of neostigmine in anesthetized man. Surv Anesthesiol. 1980; 24: 246.
94. Cronnelly R, Stanski DR, Miller RD, et al. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. 1980; 28: 78-81.
95. Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. Br J Anaesth. 1986; 58: 6S-10S.
96. Yang LPH, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009; 69: 919-942.
97. Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. Acta Anaesthesiol Taiwan. 2014; 52: 54-58.
98. Nonaka T, Fujimoto M, Nishi M, et al. The effect of rocuronium and sugammadex in hepatic tumor patients without preoperative hepatic impairment. Masui. 2013; 62: 304-308.
99. Current JD. Pharmacology for anesthetists. Mainz: PediaPress; 2004. p. 120.
100. Georgescu EF, Vasile I, Ionescu R. Intestinal pseudo-obstruction: an uncommon condition with heterogeneous etiology and unpredictable outcome. World J Gastroenterol. 2008; 14: 954-959.
101. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014; 10:1-22.
102. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. Anesthesiology. 2002; 96: 45-50.
103. Mirakhur RK, Dundee JW, Clarke RS. Glycopyrrolate-neostigmine mixture for antagonism of neuromuscular block: comparison with atropine-neostigmine mixture. Br J Anaesth. 1977; 49: 825-829.
104. Cheng C-R, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg. 2005; 101: 1349-1355.
105. Løvstad RZ, Thagaard KS, Berner NS, et al. Neostigmine 50 mug kg-1 with glycopyrrolate increases postoperative nausea in women after laparoscopic gynaecological surgery. Acta Anaesthesiol Scand. 2001; 45: 495-500.
106. Gottlieb JD, Sweet RB. The antagonism of curare: the cardiac effects of atropine and neostigmine. Can Anaesth Soc J. 1963; 10: 114-121.
107. Erbaş M, Toman H, Sahin H, et al. Comparison of effects of sugammadex and neostigmine on QTc prolongation in rabbits under general anesthesia. Acta Cir Bras. 2014; 29: 807-811.
108. Pratt CI. Bronchospasm after neostigmine. Anaesthesia. 1988; 43: 248.
109. Schubert MM, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. J Dent Res. 1987; 66: 680-688.
110. Sasaki N, Meyer MJ, Malviya SA, et al. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: a prospective study. Anesthesiology. 2014; 121: 959-968.
111. Herbstreit F, Zigrahn D, Ochterbeck C, et al. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2010; 113: 1280-1288.
112. Eikermann M, Fassbender P, Malhotra A, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology. 2007; 107: 621-629.
113. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009; 64 (Suppl 1): 22-30.
114. Miller RD, Van Nyhuis LS, Eger EI, et al. Comparative times to peak effect and durations of action of neostigmine and pyridostigmine. Anesthesiology. 1974; 41: 27-32.
115. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011; 31: 691-701.
116. Questions and answers on pyridostigmine bromide [Internet]. [cited 2015 Nov 22]. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/ucm130342.htm
117. Caldwell JE, Miller RD. Clinical implications of sugammadex. Anaesthesia. 2009; 64 (Suppl 1): 66-72.
118. Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008; 109: 816-824.
119. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007; 104: 569-574.
120. Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008; 100: 622-630.
121. Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009; 110: 1020-1025.
122. Curtis R, Lomax S, Patel B. Use of sugammadex in a cant intubate, cant ventilate situation. Br J Anaesth. 2012; 108: 612-614.
123. Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg. 2013; 117: 345-351.
124. Le Corre F, Nejmeddine S, Fatahine C, et al. Recurarization after sugammadex reversal in an obese patient. Can J Anaesth. 2011; 58: 944-947.
125. De Kam P-J, Grobara P, Prohn M, et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014; 52: 227-236.
126. Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology. 2014; 121: 969-977.
127. Zwiers MA, van den Heuve M, Smeets J, et al. Assessment of the potential for displacement interactions with sugammadex. Clin Drug Investig. 2011;2:101-111.
128. Kam P-JD, van den Heuvel MW, Grobara P, et al. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex. Clin Drug Investig. 2012; 32: 203-212.
129. Schneider HJ. Supramolecular systems in biomedical fields. 2013. p. 1-51. doi: 10.1039/9781849737821.
130. Miskolczy Z, Megyesi M, Tárkányi G, et al. Inclusion complex formation of sanguinarine alkaloid with cucurbit[7]uril: inhibition of nucleophilic attack and photooxidation. Org Biomol Chem. 2011; 9: 1061-1070.
131. Ma D, Zhang B, Hoffmann U, et al. Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents invitro and reverse neuromuscular block in vivo. Angew Chem Int Ed. 2012; 51: 11358-11362.
132. Ma D, Hettiarachchi G, Nguyen D, et al. Acyclic cucurbit[n]uril molecular containersenhance the solubility and bioactivity of poorlysoluble pharmaceuticals. Nat Chem. 2012; 4: 503-510.
133. Ma D, Glassenberg R, Ghosh S, et al. Acyclic cucurbituril congener binds to local anaesthetics. Supramol Chem. 2012; 24: 325-332.
134. Dahaba AA, Bornemann H, Hopfgartner E, et al. Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia. Br J Anaesth. 2012; 108: 602-606.